Telix Pharmaceuticals Rises for Second Day After FDA Approval of Pixclara
Telix Pharmaceuticals (TLX) is up approximately 11% in Tuesday trading as the stock continues to benefit from recent U.S. Food and Drug Administration approval of its diagnostic drug, Pixclara (floretyrosine F 18). The FDA approved Pixclara for use in evaluating patients with brain cancer. The approval marks a significant milestone for Telix, which is an Australian-based radiopharmaceutical company listed on the ASX. Pixclara's authorization by the FDA follows its earlier approval in Australia and Europe, expanding its market reach to include U.S. healthcare providers treating neuroendocrine tumors and brain cancer patients. The stock has seen a positive reaction from investors following this regulatory success, with continued gains observed for two consecutive trading days.
Tickers: $TLX
Topics: brain cancer diagnostic drugs fda approval pharmaceuticals